In vitro susceptibilities of Entamoeba histolytica to azithromycin, CP-63,956, erythromycin, and metronidazole.
Current therapy of Entamoeba histolytica infection requires use of multiple agents effective at different body sites, including the intestinal lumen, intestinal tissue, and liver. Azithromycin and CP-63,956, new extended-half-life macrolides which reach high levels in tissue, exhibit in vitro antiam...
Na minha lista:
| Publicado no: | Antimicrob Agents Chemother |
|---|---|
| Principais autores: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Microbiology (ASM)
1989
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC284263/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/2548442/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.33.6.960 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|